| 13:28:03 | 13:28:03 | 7 Aug 2026 | | Exercise of Warrants |
| 20/07/26 | 07:00:07 | 20 Jul 2026 | | Completion of Dosing in Toxicology Programme |
| 22/06/26 | 09:40:15 | 22 Jun 2026 | | Publication of Phase 1 data on SDC-1801 in BJCP |
| 01/05/26 | 07:00:05 | 1 May 2026 | | Exercise of Warrants |
| 12/03/26 | 07:00:09 | 12 Mar 2026 | | Half-Year Report for Six Months Ended 31 Dec 2025 |
| 03/03/26 | 07:00:09 | 3 Mar 2026 | | Notice of Results and Investor Presentation |
| 17/02/26 | 07:00:09 | 17 Feb 2026 | | Restart of Phase 2-enabling toxicology programme |
| 23/01/26 | 16:36:04 | 23 Jan 2026 | | Form 8.3 - Oxford Biomedica plc |
| 09/12/25 | 16:25:51 | 9 Dec 2025 | | Results of AGM |
| 09/12/25 | 07:00:02 | 9 Dec 2025 | | Annual General Meeting Statement |
| 17/11/25 | 07:00:13 | 17 Nov 2025 | | Notice of AGM, Annual Report and Accounts |
| 30/10/25 | 07:00:14 | 30 Oct 2025 | | Appointment of Joint Corporate Broker |
| 23/10/25 | 07:00:09 | 23 Oct 2025 | | Preliminary Results for Year Ended 30 June 2025 |
| 10/10/25 | 07:00:07 | 10 Oct 2025 | | Update on toxicology study for SDC-1801 |
| 07/10/25 | 07:00:11 | 7 Oct 2025 | | Notice of Results and Investor Presentation |
| 26/09/25 | 15:12:20 | 26 Sept 2025 | | Exercise of Warrants |
| 18/09/25 | 12:59:20 | 18 Sept 2025 | | Exercise of Warrants |
| 26/08/25 | 07:00:13 | 26 Aug 2025 | | Exercise of Warrants |
| 20/08/25 | 10:01:59 | 20 Aug 2025 | | Exercise of Warrants |
| 12/08/25 | 07:00:05 | 12 Aug 2025 | | Sareum Collaboration with Receptor.AI |
| 09/07/25 | 07:00:08 | 9 Jul 2025 | | Exercise of Warrants |
| 04/07/25 | 07:00:01 | 4 Jul 2025 | | Appointment of Sole Broker |
| 29/05/25 | 07:00:03 | 29 May 2025 | | Initiation of Toxicology Studies for SDC-1801 |
| 28/04/25 | 07:00:06 | 28 Apr 2025 | | Update on TYK2/JAK1 and SRA737 Programmes |
| 24/04/25 | 07:00:12 | 24 Apr 2025 | | Exercise of Warrants |
| 27/03/25 | 07:00:15 | 27 Mar 2025 | | Director’s Dealing |
| 25/03/25 | 07:00:02 | 25 Mar 2025 | | Sareum Half-Year Report |
| 20/03/25 | 07:00:12 | 20 Mar 2025 | | Notice of HY Results and Investor Presentation |
| 13/03/25 | 07:15:19 | 13 Mar 2025 | | Institutional Equity Fundraise |
| 13/03/25 | 07:08:43 | 13 Mar 2025 | | Sareum Acquires Licence for SRA737 |
| 31/12/24 | 07:00:04 | 31 Dec 2024 | | Update on SRA737 |
| 19/12/24 | 16:07:55 | 19 Dec 2024 | | Results of AGM |
| 19/12/24 | 07:00:06 | 19 Dec 2024 | | AGM Statement |
| 18/12/24 | 07:00:07 | 18 Dec 2024 | | Appointment of Joint Broker |
| 17/12/24 | 09:14:35 | 17 Dec 2024 | | Holding(s) in Company |
| 16/12/24 | 07:00:04 | 16 Dec 2024 | | Award of Share Options |
| 27/11/24 | 09:38:19 | 27 Nov 2024 | | Notice of AGM, Annual Report and Accounts |
| 29/10/24 | 07:00:04 | 29 Oct 2024 | | Final Results for the Year Ended 30 June 2024 |
| 23/10/24 | 07:00:09 | 23 Oct 2024 | | Notice of Final Results and Investor Presentation |
| 21/10/24 | 07:00:04 | 21 Oct 2024 | | Further Subscription to raise £1,000,000 |
| 11/10/24 | 07:00:05 | 11 Oct 2024 | | Subscription to raise £2,364,000 |
| 16/09/24 | 07:00:03 | 16 Sept 2024 | | Patent Allowance in China |
| 02/09/24 | 07:00:09 | 2 Sept 2024 | | US patent allowance |
| 10/07/24 | 07:00:09 | 10 Jul 2024 | | Management Changes |
| 01/07/24 | 07:00:04 | 1 Jul 2024 | | Positive Data from SDC-1801 Phase 1 Clinical Trial |
| 30/05/24 | 07:00:14 | 30 May 2024 | | Appointment of Sole Broker |
| 07/05/24 | 14:10:05 | 7 May 2024 | | Exercise of Warrants |
| 23/04/24 | 07:00:06 | 23 Apr 2024 | | Final Issue of RiverFort Subscription Shares |
| 19/04/24 | 11:35:10 | 19 Apr 2024 | | Issue of RiverFort Subscription Shares |
| 15/04/24 | 15:28:52 | 15 Apr 2024 | | Issue of RiverFort Subscription Shares |
